tRNA-derived fragments (tRFs) have been defined as a novel class of small noncoding RNAs. tRFs have been reported to be deregulated in cancer, but their biologic function remains to be fully understood. We have identified a new tRF (named tRF3E), derived from mature tRNAGlu, that is specifically expressed in healthy mammary glands but not in breast cancer (BC). Consistently, tRF3E levels significantly decrease in the blood of patients with epidermal growth factor receptor 2 (HER2)-positive BC reflecting tumor status (control > early cancer > metastatic cancer). tRF3E down-regulation was recapitulated in D16HER2 transgenic mice, representing a BC preclinical model. Pulldown assays, used to search for proteins capable to selectively bind tRF3E, have shown that this tRF specifically interacts with nucleolin (NCL), an RNA-binding protein overexpressed in BC and able to repress the translation of p53mRNA.The binding properties ofNCL-tRF3E complex, predicted in silico and analyzed byEMSA assays, are congruent with a competitive displacement of p53 mRNA by tRF3E, leading to an increased p53 expression and consequently to a modulation of cancer cell growth. Here, we provide evidence that tRF3E plays an important role in the pathogenesis of BC displaying tumor-suppressor functions through a NCL-mediated mechanism.—Falconi, M.,Giangrossi, M., Elexpuru Zabaleta, M.,Wang, J.,Gambini,V., Tilio, M., Bencardino, D., Occhipinti, S., Belletti, B., Laudadio, E., Galeazzi, R., Marchini, C., Amici, A. A novel 39-tRNAGlu-derived fragment acts as a tumor-suppressor in breast cancer by targeting nucleolin.

A novel 39-tRNAGlu-derived fragment acts as a tumor-suppressor in breast cancer by targeting nucleolin

Falconi M.;GiangrossiM.;Wang J.;Gambini V.;TilioM.;Bencardino D.;Occhipinti S.;Marchini C.;Amici A.
2019

Abstract

tRNA-derived fragments (tRFs) have been defined as a novel class of small noncoding RNAs. tRFs have been reported to be deregulated in cancer, but their biologic function remains to be fully understood. We have identified a new tRF (named tRF3E), derived from mature tRNAGlu, that is specifically expressed in healthy mammary glands but not in breast cancer (BC). Consistently, tRF3E levels significantly decrease in the blood of patients with epidermal growth factor receptor 2 (HER2)-positive BC reflecting tumor status (control > early cancer > metastatic cancer). tRF3E down-regulation was recapitulated in D16HER2 transgenic mice, representing a BC preclinical model. Pulldown assays, used to search for proteins capable to selectively bind tRF3E, have shown that this tRF specifically interacts with nucleolin (NCL), an RNA-binding protein overexpressed in BC and able to repress the translation of p53mRNA.The binding properties ofNCL-tRF3E complex, predicted in silico and analyzed byEMSA assays, are congruent with a competitive displacement of p53 mRNA by tRF3E, leading to an increased p53 expression and consequently to a modulation of cancer cell growth. Here, we provide evidence that tRF3E plays an important role in the pathogenesis of BC displaying tumor-suppressor functions through a NCL-mediated mechanism.—Falconi, M.,Giangrossi, M., Elexpuru Zabaleta, M.,Wang, J.,Gambini,V., Tilio, M., Bencardino, D., Occhipinti, S., Belletti, B., Laudadio, E., Galeazzi, R., Marchini, C., Amici, A. A novel 39-tRNAGlu-derived fragment acts as a tumor-suppressor in breast cancer by targeting nucleolin.
File in questo prodotto:
File Dimensione Formato  
FASEB 2019.pdf

accesso aperto

Descrizione: Articolo
Tipologia: Versione Editoriale
Licenza: DRM non definito
Dimensione 1.36 MB
Formato Adobe PDF
1.36 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11581/431197
Citazioni
  • ???jsp.display-item.citation.pmc??? 25
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 25
social impact